Amy Hempstead is a Product Development and Commercialization Leader with extensive experience in the biotechnology sector, primarily at Biogen. They held various roles including Senior Product Manager for US Neurology Marketing, where they focused on marketing strategy for products such as Tysabri and Tecfidera. In their later position as Sr. Director, they served as Global Asset Executive for Dapirolizumab pegol, managing systemic lupus erythematosus (SLE) development and commercialization. Amy earned a BS in Neuroscience from Bates College in 2004.
This person is not in any teams
This person is not in any offices